FDA Requests Recall of All Ranitidine Heartburn Drugs (Zantac) from Market.
The United States Food and Drug Administration (FDA) announced on April 1, 2020 that it was requesting that manufacturers withdraw and remove all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately due to the potential for consumer exposure to unacceptable levels of the human carcinogen known as N-Nitrosodimethylamine (NDMA).
According to the FDA, the Ranitidine and Zantac recall means ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S.
According to the FDA’s announcement, FDA testing and evaluation confirmed that NDMA levels increase in ranitidine even under normal storage conditions and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers. The FDA stated that testing showed that the older a ranitidine product is or the longer the length of time since it was manufactured, the greater the level of NDMA. These conditions may raise the level of NDMA in the ranitidine product above the acceptable daily intake limit.
If you used ranitidine or Zantac and were diagnosed with cancer, you may be able to seek compensation from a Zantac cancer lawsuit.
If You Have Thoughts On The Zantac & Ranitidine Recall, Share Your Comments Below.